Sydney, 5 July 2023 – AdvanCell Isotopes, a Sydney-based radiopharmaceutical company, has been honoured with the prestigious International Red Dot Design Award for its revolutionary Alpha Isotope Generator. The device, designed by leading Australian product development consultancy Design + Industry (D+I), has been recognised for its outstanding design and innovation in the field of targeted alpha therapies.

The Red Dot Design Award, one of the most esteemed design accolades globally, celebrates excellence in design and recognises products that exhibit exceptional aesthetics, functionality, and user experience. With entries received from 60 countries, the competition showcased a diverse range of products that underwent a rigorous evaluation process by a panel of 43 international design experts.

The Alpha Isotope Generator developed by AdvanCell addresses a critical need in cancer treatment by providing a reliable, scalable, and quality-controlled supply of the rare isotope required for targeted alpha therapies. This groundbreaking technology offers a decentralised solution, eliminating supply bottlenecks associated with conventional manufacturing methods and improving patient access to life-saving treatments.

According to the Red Dot jury, the AdvanCell ²¹²Pb Generator impressed with its innovative design that successfully transferred highly complex technology into a transportable device. The intuitive controls, reduced appearance, and the combination of white and stainless-steel finishes create a clear reference to the medical environment, instilling user trust and confidence.

Commenting on the win, David Jones, Head of D+I, said, "We are thrilled to see Red Dot recognise the Alpha Isotope Generator. This recognition highlights the dedication and ingenuity of the AdvanCell and D+I teams in developing this game-changing device that will significantly impact accessibility, allowing a great deal more patients across large geographical areas to access radiopharmaceutical treatments."

This award marks yet another milestone for Design + Industry, whose commitment to translating research concepts into tangible product solutions has earned them several accolades for the compliant design and development of innovative medical devices and instruments (ISO 13485:2016), including the Australian Good Design Award of the Year for the AdvanCell Generator in 2022, and the Inventia Life Science RASTRUM 3D Bio-Printer in 2019.

The Red Dot Design Award win solidifies AdvanCell's position as a leading player in the global radiopharmaceutical market. With the Targeted Alpha Therapy market segment projected to experience over 20% growth per year and an expected market value of USD $30 billion by 2030, AdvanCell's cutting-edge technology is poised to revolutionise cancer treatment worldwide.